NUDCD1 antibody (AA 431-530) (HRP)

Catalog No. ABIN6944329

The Rabbit Polyclonal anti-NUDCD1 antibody has been validated for WB, ELISA, IHC (p) and IHC (fro). It is suitable to detect NUDCD1 in samples from Mouse.

Quick Overview for NUDCD1 antibody (AA 431-530) (HRP) (ABIN6944329)

Target: NUDCD1 (NudC Domain Containing 1 (NUDCD1))

Reactivity: Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This NUDCD1 antibody is conjugated to HRP

Application: Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Product Details anti-NUDCD1 Antibody (HRP)

Binding Specificity: AA 431-530

Cross-Reactivity: Mouse

Predicted Reactivity: Human,Rat,Dog,Cow,Sheep,Horse,Rabbit,Zebrafish

Purification: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human NUDCD1

Isotype: IgG

Application Details

Application Notes: WB 1:300-5000
IHC-P 1:200-400
IHC-F 1:100-500

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Expiry Date: 12 months

Target Details for NUDCD1

Target: NUDCD1 (NudC Domain Containing 1 (NUDCD1))

Alternative Name: NUDCD1

Background:

Synonyms: 4921532K09Rik, AA407246, AW260430, AW556235, Chronic myelogenous leukemia tumor antigen 66, CML66, CML66 L, FLJ14991, NudC domain containing 1, NudC domain-containing protein 1, NUDC1_HUMAN, nudcd1, OVA66, RGD1310624, Tumor antigen CML66.

Background: The NUDCD1 gene encodes the 583 amino acid CML66 protein which demonstrates expression in a variety of solid tumor cell lines and leukemias. Expression of CML66 in normal tissues is restricted to testis and heart. The CML66 antibody is found in sera of 18-38 % of patients with lung cancer, melanoma or prostate cancer. These findings indicate that CML66 may be immunogenic in a wide variety of malignancies and may be a target for antigen-specific immunotherapy. A short isoform of CML66, designated CML66-S, is a product of alternative splicing. CML66-S has the same C-terminus as full-lenghth CML66 (also designated CML66-L), but has a unique N-terminus. CML66-S shows predominant expression in testis, and is also expressed in very low levels in tumor cells, while CML66 is expressed in tumor cells and testis.

Gene ID: 84955

UniProt: Q96RS6